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lected patients undergoing catheterization and/or PCI. Bedside measure of
whole blood Hemonox Clotting Time (CT) and activated Partial Prothrombin
Time (aPTT) were measured at baseline (T1) and 10’ after the IV administra-
tion of enoxaparin (T2) in patients receiving additional enoxaparin and com-
pared to differed plasma chromogenic anti-Xa (AXA) activity measurement.
Results: Median [IQR] values were 0.1 [0.1-0.1] and 0.87 [0.74-1.03] IU/
mL for AXA; 74 [70-81] and 143 [114-206] sec for Hemonox CT, and 44 [39-
50] and 72 [58-93] sec for aPTT at T1 and T2 time points, respectively.
Hemonox CT strongly correlated with Anti-Xa level spearman r=0.81 (95% CI
0.77-0.84, p<0.0001). When comparing a total of 486 values to discriminate
patients with AXA <0.5 IU/mL, the area under the receiver operating curve
(AUC) for Hemonox CT was 0.95 ± 0.01 (95% IC; 0.93-0.97; p<0.0001)
versus 0.89 ± 0.01 (95% IC; 0.86-0.92; p<0.0001) for aPTT. A threshold
Hemonox CT value of 120 sec was associated with a 94.9% (95% CI 91.1-
97.4) sensitivity and a 73.3% (95% IC 67.6-78.5) specificity with a likelihood
ratio = 3.5 to detect patients with inadequate anti-Xa level (<0.5UI/mL). With
this threshold the positive predictive and negative predictive values of
Hemonox CT as a diagnosis test were 73.9% (95% IC 68.7-79.0) and 94.78%
(95% IC 91.8-97.8) respectively.
Conclusion: According to the results of this study Hemonox CT appears to
be a fast and reliable bedside test that could be used to adjust enoxaparin anti-
coagulation in PCI. 
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Background: Percutaneous coronary interventions (PCI) are proposed with
increasing frequency to elderly and very elderly patients (pts) owing to the
high prevalence of coronary disease in this age group. There are limited data
about differences between aged and very aged pts in respect to risk factors, co
morbidities and outcomes after PCI.
Objectives: We sought to define the differences in clinical presentation
and outcomes in different age classes in elderly pts treated by PCI with stent
implantation.
Methods: 1955 pts aged >75 years (62% men, mean age 80.3±3.8 years)
treated by 2072 PCI with 3352 stents implantations were prospectively
included in this study.
Results: There were 936 pts (47.8%) aged 75-80 years, 707 pts (36.2%)
between 81 and 85 years and 312 pts (16.0%) aged >85 years. Elderly and
very elderly pts had less cardiovascular risk factors (hypercholesterolemia:
58% vs 54% vs 45%, p=0.01, diabetes: 36% vs 35% vs 32%, p=0.02, familial
history of ischemic heart disease: 17% vs 12% vs 9.3%, p=0.002) but more
often renal failure at admission (48% vs 65% vs 72% p<0.001). Unstable coro-
nary syndromes as n indications for stenting increased with age (37% vs 44%
vs 51%) p<0.001) as well as lesions concerning left main coronary disease or
bypass grafts (p=0.04). 6-month cardiac mortality rate increased with age
(1.6% vs 2.8% vs 5.2%, p=0.008) as well as cerebral vascular events (0.1% vs
0.8% vs 1.2%, p=0.03) while the rate of non fatal myocardial infarction
remained similar (1.4 % vs 2.0 % vs 2.4%, p=NS).
Conclusion: there are several difference in clinical presentation and 6-
month outcomes in different age classes in elderly pts with ischemic heart
disease treated by PCI with stent implantation with worse results in very
elderly (>85%) pts.
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Background: Primary angioplasty for acute myocardial infarction (PAMI)
proved superior to thrombolysis in many major trials. However, PAMI is
available in only limited number of centers particularly in developing coun-
tries. On the other hand, it was clearly shown that thrombolysis when given
early is associated with a comparable outcome to PAMI. It is however not
known if this can apply to streptokinase (SK) that is the most widely used lytic
agent in developing countries.
Objective: The aim of this study was to assess the in-hospital outcome of
patients given early thrombolysis using SK.
Methods: From the Monastir AMI registry including 1148 patients, 403
received SK therapy. This population was divided into three groups based on
the delay between the onset of symptoms and treatment: Group I: 0 – 3 hours
(n= 208), Group II: 3 – 6 hours (n= 145) and Group III more than 6 hours (n
= 50). Mean age was 60.3 +/- 12 years, 349 (86.6 %) were male. Baseline cha-
racteristics were similar between the three groups.
Results: Clinical reperfusion defined as sedation of chest pain and ST ele-
vation regression for more than 50% from baseline was observed in 75.1 % of
Group I, 58.8% of Group 2 and in 46.8 % of Group 3 pts. ( p < 0.01 ). In
hospital mortality and complications are compared between the three groups
in the table below.
Conclusion: Early thrombolysis (less than 3 hours from chest pain onset)
using streptokinase is associated with a very high percentage of clinical reper-
fusion (75%), a lower rate of heart failure and mortality. These results have
important clinical implications particularly in developing countries.
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ROC for Hemonox CT and aPTT to detect Axa<0.5UI/ml
Group I Group II Group III p
Heart failure 31 (14.9%) 37 (25.5%) 18 (36%) 0.001
Ventricular 
fibrillation
8 (3.8%) 10 (6.9%) 2 (4%) 0.407
Ventricular 
tachycardia
6 (2.9%) 10 (6.9%) 4 (8%) 0.133
Pericarditis 10 (4.8%) 7 (4.8%) 4 (8%) 0.636
Death 14 (6.7%) 9 (6.2%) 7 (14%) 0.166
